1. Does nebivolol have renoprotective action in patients with chronic kidney disease conditions? An integrative review.
- Author
-
Araújo Encinas JF, Foncesca Peiró CH, Perez MM, Santos Raimundo JR, de Gois KC, Peres MC, Draghi PF, Costas Arcia CG, Simões DP, Murad N, da Costa Aguiar Alves B, Affonso Fonseca FL, and Luciano da Veiga G
- Subjects
- Adrenergic beta-3 Receptor Antagonists pharmacology, Adrenergic beta-3 Receptor Antagonists therapeutic use, Animals, Humans, Hypertension drug therapy, Menopause drug effects, Receptors, Adrenergic, beta-3, Nebivolol pharmacology, Nebivolol therapeutic use, Protective Agents pharmacology, Protective Agents therapeutic use, Renal Insufficiency, Chronic drug therapy
- Abstract
Systemic arterial hypertension (SAH) is a chronic disease of multifactorial origin and one of the main risk factors for major adverse cardiovascular events (MACE), which are the leading causes of morbidity and mortality worldwide. The pharmacological treatment of SAH involves five main classes of drugs, and Nebivolol (NEB) is one of those drugs, belonging to the class of third generation β1-adrenoceptors selective blockers. NEB is composed of a racemic mixture of two enantiomers: d-nebivolol, which exerts antagonist effects on β
1 -adrenoceptors, and l-nebivolol, a vascular β3 receptor agonist. There are several studies that report different actions of NEB, not only for the treatment of SAH, but also as an antioxidant agent or even as a protector of renal damage. The aim of this systematic review was to investigate the available evidence regarding the effects of NEB on kidney diseases, evaluating its possible renoprotective action., (Copyright © 2021. Published by Elsevier B.V.)- Published
- 2021
- Full Text
- View/download PDF